Respiratory
β2-Adrenergic agonists
Bronchodilators: short-acting drugs relieve symptoms within minutes; long-acting ones are added to inhaled corticosteroids for control.
Mécanisme d’action
- Inhaled β2 agonists stimulate β2 receptors on airway smooth muscle and relax it directly, opening the airways.
- They have no anti-inflammatory effect, so they do not treat the underlying airway inflammation.
- Short-acting drugs (SABAs) act in 5 to 30 minutes and last 4 to 6 hours; long-acting drugs (LABAs) last at least 12 hours.
Cibles moléculaires
- β2-adrenergic receptor on airway smooth muscle: Agonist
Médicaments : β2-Adrenergic agonists
Short-acting (SABA): relievers
- Salbutamol (albuterol) (Short-acting reliever.)
- Terbutaline (Short-acting.)
Long-acting (LABA)
- Salmeterol (Long-acting.)
- Formoterol (Long-acting, with a fast onset.)
Indications thérapeutiques
- Quick relief of bronchospasm: every patient with asthma should have a short-acting reliever
- Mild intermittent asthma and exercise-induced bronchospasm (short-acting drug alone)
- Persistent asthma not controlled by an inhaled corticosteroid: a long-acting drug is added, usually in a combination inhaler
- COPD: long-acting drugs (LABAs), with or without a LAMA, are first-line maintenance bronchodilators
Maladies traitées
Effets indésirables
- Tachycardia
- Tremor
- Hypokalaemia
- Hyperglycaemia
- Hypomagnesaemia
- All much less with inhaled than with systemic doses
Contre-indications selon le terrain
- Myocardial infarction (Avec précaution): Stimulating the heart causes tachycardia and can provoke angina or arrhythmias.
- Graves disease (Avec précaution): Tremor and tachycardia add to those of thyrotoxicosis.
- Low potassium (Avec précaution): They drive potassium into cells and lower its plasma level.
Autres précautions et interactions
- Short-acting drugs alone are not enough for persistent asthma.
- Long-acting drugs must never be used without an inhaled corticosteroid.
Sujets liés
Rédigé d’après
- Lippincott Illustrated Reviews: Pharmacology, 7th ed., Ch. 39, Drugs for Disorders of the Respiratory System, II.C β2-Adrenergic agonists
Ressource pédagogique. Ne constitue pas un avis, un diagnostic ou un traitement médical.